Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
ARVINAS, INC. (ARVN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant , including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2- metastatic breast cancer –"
06/08/2023 8-K Investor presentation
Docs: "EXHIBIT 99.1 Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line",
"June 8, 2023 ARV-766: Phase 1 and"
05/05/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/23/2023 8-K Quarterly results
Docs: "Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update – Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer –"
01/09/2023 8-K Investor presentation
Docs: "J.P. Morgan Healthcare Conference January 11, 2023"
12/16/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/21/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
08/19/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
Docs: "Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update"
02/17/2022 8-K Investor presentation
Docs: "Arvinas PROTAC ® Protein Degrader Bavdegalutamide Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer",
"Company Presentation"
02/14/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC ® Degrader Bavdegalutamide to be Presented at 2022 ASCO GU Meeting"
12/10/2021 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
09/28/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
08/06/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Equity Distribution Agreement, by and among Arvinas, Inc., Piper Sandler & Co. and Cantor Fitzgerald & Co",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP"
08/05/2021 8-K Quarterly results
07/22/2021 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Secur...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"COLLABORATION AGREEMENT BY AND AMONG ARVINAS, INC., ARVINAS OPERATIONS, INC., ARVINAS ESTROGEN RECEPTOR, INC. AND PFIZER INC. DATED AS OF JULY 21, 2021",
"Stock Purchase Agreement, by and between Arvinas, Inc. and Pfizer, Inc",
"INVESTOR AGREEMENT By and Between PFIZER INC. AND ARVINAS, INC. Dated as of July 21, 2021",
"Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC ® Protein Degrader ARV-471",
"Excerpts from Arvinas, Inc. presentation"
06/09/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/06/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/18/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Arvinas, Inc. and Goldman Sachs & Co. LLC and Piper Sandler & Co., as representatives of the underwriters named therein",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock NEW HAVEN, Conn., December 15, 2020 - Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to an additional 857,142 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by Arvinas. Goldman Sachs & Co. LLC and Piper Sandler & Co. are acting as join..."
12/14/2020 8-K Investor presentation
Docs: "Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC ® Protein Degraders ARV-471 and ARV-110",
"Company Presentation"
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy